Hormonal
Semaglutide demonstrates superior weight loss and glycemic control compared to other GLP-1RAs like liraglutide and dulaglutide, with weight loss ranging from 10% to over 20%.
Semaglutide (Wegovy) is a once-weekly injection that has shown significant weight loss (10-20%) in clinical trials, outperforming other drugs in its class. It is approved for chronic weight management in adults and adolescents. You must combine it with diet and exercise. Be aware that it is expensive and may face supply shortages due to high demand.
Patients using semaglutide at varying doses experienced weight loss ranging from 10% to over 20%, surpassing the results seen with liraglutide administered through daily injections.
Why this rating
Based on FDA approval from multiple clinical trials involving over 4,000 subjects.
Source
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
Alexander C. Martins et al. · Exploration of Drug Science · 2024
DOI 10.37349/eds.2024.00039
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide facilitate weight loss and glycemic control by delaying gastric emptying, stimulating insulin release, and suppressing glucagon secretion.Good
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior weight loss and metabolic improvements compared to selective GLP-1RAs, insulin, and placebo.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →